HIPPUTOPE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIPPUTOPE is an injectable diagnostic or therapeutic agent developed by Bracco, approved in 1970. The specific mechanism of action and indication are not publicly detailed in available data. This product represents a legacy pharmaceutical asset with over 50 years of market history.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), indicating transition phase requiring defensive positioning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching status indicate limited active hiring for HIPPUTOPE. Career opportunities are concentrated in portfolio transition, cost optimization, and compliance roles rather than growth-oriented positions.
Brand ManagerProduct Manager
Worked on HIPPUTOPE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.